I was hoping it would have increased by the £8,000 I'm transferring out of my work pension, but Legal & General have excelled themselves with their incompetence. The transfer was supposed to happen within 10 days, but rather than get it out of the way before force selling my funds as I had planned, they have decided to go ahead with that sale and re-investment even though I never wanted it. Bloody useless. As a result they are delaying the transfer until 30th October, by which time all the current bargain shares will probably have recovered. Based on this performance I'll be transferring cash out of that pension as frequently as possible, just using it as a way of getting the employer contributions. I have absolutely no confidence in them not to cock things up even more than the £600 they've already cost me.
Worst performer this week (other than Legal & General) was KIBO:Kibo Energy which is on very shaky ground now. The fact that their "great working relationship" with the authorities has metamorphosed into a request to submit tenders suggests that it's not such a cosy relationship after all. Endless delays had been tolerable because of the potential benefits, but now it's looking like the delays are just stalling and nothing is ever going to happen. I'm preparing myself for the worst now, and may have to wave goodbye to £2,000 which will have a heavy impact on my performance figures. These dropped 6% this week and are 66% down on my purchase price.
That was the only big drop this week, at least percentage wise as OPTI:Optibiotix only fell 3% but it cost me £1,500.
CAML:Central Asia Metals may have started a gradual climb, up 5% this week and one of the target shares for when my pension transfer arrives.
IQE:IQE were also up 5%, and I'm tempted to get some at sub 90p as those shorts have got to close some time, and 5g is getting nearer. The announcement that they are producing from the new reactors could see a bit of a re-rate.
SBTX:SkinBioTherapeutics usually follows OPTI:Optibiotix, but climbed 7% this week probably in anticipation of imminent news on the human trials.
Share of the Week was PAF:Pan African Resources which climbed 8% and is now 16% in profit. I have high hopes that this can double quite quickly when the announcement is made that the new project is producing. It's always been a well run company, but with a few recent issues and suspension of the dividend has been hit hard. They seem to be through that now, and given the generosity of the dividend in the past, I'm confident there will be a good re-rate.
I guess a shallower decline is an improvement!
Here's the performance of the ISA and share accounts
| Weekly Change | |||
| Cash | £25.99 | +£0 | |
| Portfolio cost | £56,958.55 | +£0 | |
| Portfolio sell value (bid price - commission) | £53,612.09 | (-5.9%) | -£991.28 |
| Potential profits | £5,801.37 | -£1,011.92 | |
| Yr 4 Dividends | £52.69 | +£0 | |
| Yr 4 Profit from sales | £814.53 | +£0 | |
| Yr 4 Average monthly cash profit | £337.20 | (7.1%) | -£33.72 |
| Total Dividends | £1,291.02 | +£0 | |
| Total Profit from sales | £19,511.65 | +£0 | |
| Average monthly cash profit | £535.69 | (11.3%) | -£3.23 |
| (Sold stocks profit + Dividends - Fees / Months) |
Profits down due to OPTI:Optibiotix, but a few quid in improving losses means the overall vaue dropped a little less. Not much else to talk about.
Same shape as the combined chart.
The SIPP looks like this after week 151
| Weekly Change | |||
| Cash | £30.16 | +£0 | |
| Portfolio cost | £27,893.76 | +£0 | |
| Portfolio sell value (bid price - commission) | £28,445.11 | (2%) | -£67.29 |
| Potential profits | £4,142.93 | -£157.60 | |
| Yr 3 Dividends | £292.57 | +£0 | |
| Yr 3 Profit from sales | £1,619.73 | +£0 | |
| Yr 3 Average monthly cash profit | £164.93 | (7.1%) | -£3.58 |
| Total Dividends | £1,208.67 | +£0 | |
| Total Profit from sales | £10,544.92 | +£0 | |
| Average monthly cash profit | £329.52 | (14.2%) | -£2.19 |
| (Sold stocks profit + Dividends - Fees / Months) |
The increase in potential profits for PAF:Pan African Resources and CAML:Central Asia Metals was almost enough to nullify the losses from OPTI:Optibiotix, but not quite. I think we can regard this as a flat week compared to recent ones.
That's such a narrow gap!
The trading account looks like this after week 117
| Weekly Change | |||
| Cash | £1.47 | -£150.00 | |
| Portfolio cost | £2,321.29 | +£0 | |
| Portfolio sell value (bid price - commission) | £1,779.08 | (-23.4%) | +£60.40 |
| Potential profits | £18.96 | -£8.40 | |
| Year 3 Dividends | £0 | +£0 | |
| Year 3 Profit | £177.06 | +£0 | |
| Yr 3 Average monthly cash profit | £59.02 | (30.5%) | -£4.92 |
| Dividends | £1.15 | +£0 | |
| Profit from sales | -£64.29 | +£0 | |
| Average monthly cash profit | -£2.34 | (-1.2%) | +£0.02 |
| (Sold stocks profit + Dividends - Fees / Months) |
Coo - an account that actually increased in value! It seems like a long time since I was able to write that.
Cash reduced as I banked £150 profit after deciding I need the money. For now I won't grow the size of this account but keep the ability to have 5 shares on the go. Given the value is way below the £2,500 needed, that could be easier said than done!
Most of the gains were thanks to CAML:Central Asia Metals and IQE:IQE, but TAP:Taptica dropped in value again so potential profits are down and it's looking like I won't be selling anything in a hurry. They are quite volatile though, so could climb quickly. LION:Lionsgold issued an RNS suggesting I shouldn't hold my breath for their suspension being lifted.
Although the value increased, the removal of £150 means the green line takes a dive, but the orange line also drops as I try to take out the capital I started the account with. Once that gets to £0 I'll keep the cash in the account and allow it to grow. "If" might be the word rather than "When"!
I now know there will be no pension money next week, so not much to look forward to. I'd hoped to buy more OPTI:Optibiotix while the price was low, but can tolerate keeping my existing holding and investing in something else instead. CEY:Centamin and CAML:Central Asia Metals are the two main candidates at the moment, with maybe a small top-up of IQE:IQE.
No comments:
Post a Comment